We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Communication by Brain - Computer Interface in Amyotrophic Lateral Sclerosis:Feasibility Study

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2013 by Centre Hospitalier Universitaire de Nice.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01897818
First Posted: July 12, 2013
Last Update Posted: July 12, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Nice
  Purpose
ALS is a severe progressive neurodegenerative disease characterized by degeneration motor neurons leading to death in 3 to 5 years. Gradually in time, the patient deprived of all motor skills as well as the possibility of communication written and oral developing a state close Locked In Syndrome (LIS). The main objective is to establish the feasibility of brain-computer interface using the pathological condition, with dependent disabled subjects as a means of communication.

Condition Intervention
Amyotrophic Lateral Sclerosis Device: communication system P300 Speller

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care

Resource links provided by NLM:


Further study details as provided by Centre Hospitalier Universitaire de Nice:

Primary Outcome Measures:
  • the full achievement of "copy spelling" and "free spelling" tests session 1 [ Time Frame: 14 days after inclusion ]
  • the full achievement of "copy spelling" and "free spelling" tests session 2 [ Time Frame: 28 days after inclusion ]

Estimated Enrollment: 20
Study Start Date: July 2013
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ALS patients Device: communication system P300 Speller

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age >= 18
  • have a diagnosis of ALS suspected, possible, probable with EMG
  • be able to follow the study process and to comply with the schedule of visits upon entry into the study
  • understand the purpose of the study
  • expressing P300 wave in the conditions of the study

Exclusion Criteria:

  • have a mental illness or clinical dementia defined clinically significant may hinder the patient's ability to follow the procedures of the study
  • have a significant history of photosensitive epilepsy
  • have a history of allergy to the gel used for the electrodes
  • Major protected by law (guardianship, curators)
  • have uncorrectable visual disorders
  • not being able to maintain a sitting position and focus on a computer screen for more than 30 min.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01897818


Contacts
Contact: Claude DESNUELLE, Pr desnuelle.c@chu-nice.fr

Locations
France
Hôpital de l'Archet I Recruiting
Nice, France, 06202
Contact: Claude DESNUELLE, Pr       desnuelle.c@chu-nice.fr   
Principal Investigator: Claude DESNUELLE, Pr         
Sponsors and Collaborators
Centre Hospitalier Universitaire de Nice
  More Information

Responsible Party: Centre Hospitalier Universitaire de Nice
ClinicalTrials.gov Identifier: NCT01897818     History of Changes
Other Study ID Numbers: 12-PP-16
First Submitted: July 9, 2013
First Posted: July 12, 2013
Last Update Posted: July 12, 2013
Last Verified: May 2013

Additional relevant MeSH terms:
Sclerosis
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases


To Top